Crexont is a drug owned by Impax Laboratories Llc. It is protected by 10 US drug patents filed in 2024 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 21, 2041. Details of Crexont's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US11986449 | Levodopa dosing regimen |
Dec, 2041
(17 years from now) | Active |
| US11666538 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US10987313 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US10973769 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US10688058 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US10292935 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US10098845 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US11622941 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US12064521 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
| US11357733 | Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof |
Oct, 2034
(9 years from now) | Active |
FDA has granted several exclusivities to Crexont. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Crexont, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Crexont.
Exclusivity Information
Crexont holds 1 exclusivities out of which none have expired. Its last outstanding exclusivity is set to expire in 2027. Details of Crexont's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Aug 07, 2027 |
US patents provide insights into the exclusivity only within the United States, but Crexont is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Crexont's family patents as well as insights into ongoing legal events on those patents.
Crexont's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Crexont's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 21, 2041 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Crexont Generic API suppliers:
Carbidopa; Levodopa is the generic name for the brand Crexont. 22 different companies have already filed for the generic of Crexont, with Impax Labs having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Crexont's generic
Alternative Brands for Crexont
There are several other brand drugs in the same treatment category and using the same active ingredient (Carbidopa; Levodopa) as Crexont. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | Treatment Area | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bausch |
| |||||||||||||||
| Boehringer Ingelheim |
| |||||||||||||||
| Impax |
| |||||||||||||||
| Orion Pharma |
| |||||||||||||||
| Supernus Pharms |
| |||||||||||||||
| Teva |
| |||||||||||||||
Apart from drugs working in same treatment category, there are also some brand drugs where treatment area is different, but the active ingredient used is same i.e. Carbidopa; Levodopa. Given below is the list of those drugs and companies owning them.
| Drug Owner | Drug Name | |
|---|---|---|
| Avion Pharms |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Carbidopa; Levodopa, Crexont's active ingredient. Check the complete list of approved generic manufacturers for Crexont
About Crexont
Crexont is a drug owned by Impax Laboratories Llc. Crexont uses Carbidopa; Levodopa as an active ingredient. Crexont was launched by Impax in 2024.
Approval Date:
Crexont was approved by FDA for market use on 07 August, 2024.
Active Ingredient:
Crexont uses Carbidopa; Levodopa as the active ingredient. Check out other Drugs and Companies using Carbidopa; Levodopa ingredient
Dosage:
Crexont is available in capsule, extended release form for oral use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 70MG;280MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 52.5MG;210MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 35MG;140MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |
| 87.5MG;350MG | CAPSULE, EXTENDED RELEASE | Prescription | ORAL |